JP2006348027A - Drug for preventing or curing atopic dermatitis - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a drug for preventing or curing atopic dermatitis that is excellent in safety and preventing or curing effect on atopic dermatitis and usable in the various product forms such as medicines, foodstuffs and cosmetics. <P>SOLUTION: As the active ingredients of the drug for preventing or curing atopic dermatitis, (i) Mentha spicata and/or an extract thereof and (ii) Engelhardtiachrysolepis and/or an extract thereof are combined for use. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a preventive or therapeutic agent for atopic dermatitis. More specifically, the present invention relates to a preventive or therapeutic agent in which the preventive or therapeutic effect against atopic dermatitis is synergistically enhanced.

  Atopic dermatitis is a skin disease whose main symptom is itchy eczema that repeats exacerbations and remissions. There are type I allergies involving immediate IgE and type IV allergies that are delayed allergies. It is said that it develops by being involved in multiple ways.

  Conventionally, in the treatment of atopic dermatitis, steroids mainly composed of corticosteroids have been widely used for the purpose of suppressing itching and preventing inflammation. In addition to steroids, drugs such as antiallergic agents and antihistamines are used to suppress histamine release or to competitively inhibit H1 receptors. However, the use of steroids has the disadvantages of having side effects such as edema, hypertension, and skin cracks, and the use of drugs other than steroids has the disadvantage that the anti-inflammatory action is insufficient. Furthermore, since the above-mentioned therapeutic methods for administering the drug are merely symptomatic treatments, even if the symptoms can be temporarily alleviated, if the administration is stopped, the symptoms will recur or worsen, and the disease will be cured fundamentally. It was difficult to do.

  On the other hand, it has been reported so far that extracts of Labiatae Menta spp. Plants are useful for the prevention and treatment of atopic dermatitis (for example, see Patent Document 1). However, there is no known technique for more effectively expressing the prevention or treatment effect of atopic dermatitis possessed by the extract of the plant belonging to the genus Menaceae.

In addition, it is known that the extract of walnuts jaundice has an antiallergic effect, but there is no knowledge about the action effect obtained by combining this extract with the extract of the genus Menaceae. It is not done.
JP 2003-286181 A

  The present invention provides a prophylactic or therapeutic agent for atopic dermatitis that is highly safe, has an excellent preventive or therapeutic effect on atopic dermatitis, and can be used in various product forms such as pharmaceuticals, foods, and cosmetics. Objective.

  As a result of diligent studies to solve the above-mentioned problems, the present inventors have found that two types of plants that are used as food ingredients and have been confirmed to be safe by many years of eating experience (ie, Labiatae Menta and Walnutae). It has been found that by using a combination of jaundice) or an extract thereof, the preventive or therapeutic effect against atopic dermatitis is synergistically enhanced, and the two plants and / or extracts are further blended It has been found that pharmaceuticals, foods, cosmetics and the like are useful for the prevention or treatment of atopic dermatitis. The present invention has been completed by making further improvements based on such findings.

That is, the present invention provides a preventive or therapeutic agent of the following aspect:
Item 1-1. (i) Mental (Mentha) genus plant and / or an extract thereof, and (ii) Engelhardtia chrysolepis and / or an extract thereof as an active ingredient for preventing or preventing atopic dermatitis Therapeutic agent.
Item 1-2. Labiatae Mentha plant of the genus Mizuhakka (Mentha aquatica L.), peppermint (Mentha piperita L.), propenyl Royal mint (Mentha pulegium L.), Marubahakka (Mentha rotundifolia (L.) Huds. ), Spearmint (Mentha spicata Item 1. The agent for preventing or treating atopic dermatitis according to Item 1-1, which is at least one selected from the group consisting of L.) and Bergamot mint ( Mentha citrata (Ehrh.) Briq.).
Item 1-3. Item 11. The preventive or therapeutic agent for atopic dermatitis according to Item 1-1, wherein the Labiatae Menta plant is Atlantic mint.
Item 1-4. (i) The preventive or therapeutic agent for atopic dermatitis according to any one of Items 1-1 to 1-3, wherein the extract of the Labiatae Menta plant is obtained by extraction with a polar solvent.
Item 1-5. (i) Any one of Items 1-1 to 1-4, wherein the extract of Lamiaceae Menta genus plant is obtained by extracting from a leaf, stem, or a mixed site thereof of Lamiaceae Menta genus plant The preventive or therapeutic agent for atopic dermatitis described in 1.
Item 1-6. (ii) An extract of walnut family jaundice is obtained by extraction with a polar solvent,
Item 11. A preventive or therapeutic agent for atopic dermatitis according to any one of Items 1-1 to 1-5.
Item 1-7. (ii) The extract of the walnut family jaundice is obtained by extracting from a walnut family jaundice leaf, stem, or a mixed part thereof, A preventive or therapeutic agent for atopic dermatitis.
Item 1-8. The agent for preventing or treating atopic dermatitis according to any one of Items 1-1 to 1-7, further comprising (iii) theanine.
Item 1-9. Item 9. The preventive or therapeutic agent for atopic dermatitis according to any one of Items 1-1 to 1-8, further comprising (iv) at least one selected from the group consisting of ceramide and sugar ceramide.
Item 1-10. The prevention of atopic dermatitis according to any one of Items 1-1 to 1-7, further comprising (iii) theanine, and (iv) at least one selected from the group consisting of ceramide and sugar ceramide Therapeutic agent.
Item 1-11. Item 8. The preventive or therapeutic agent for atopic dermatitis according to any one of Items 1-1 to 1-7, further comprising theanine, ceramide, and sugar ceramide.

The present invention also provides a food according to the following embodiment:
Item 2-1. Item 15. A food containing the preventive or therapeutic agent for atopic dermatitis according to any one of Items 1-1 to 1-11.
Item 2-2. Item 15. A food for preventing or treating atopic dermatitis, comprising the agent for preventing or treating atopic dermatitis according to any one of Items 1-1 to 1-11.
Item 2-3. A food containing (i) a Labiatae plant and / or an extract thereof, and (ii) a walnut jaundice and / or an extract thereof.
Item 2-4. Labiatae Mentha plant of the genus Mizuhakka (Mentha aquatica L.), peppermint (Mentha piperita L.), propenyl Royal mint (Mentha pulegium L.), Marubahakka (Mentha rotundifolia (L.) Huds. ), Spearmint (Mentha spicata The food according to Item 2-3, which is at least one selected from the group consisting of L.) and Bergamot mint ( Mentha citrata (Ehrh.) Briq.).
Item 2-5. The food according to Item 2-3, wherein the Labiatae Menta plant is Atlantic mint.
Item 2-6. (i) The food according to any one of Items 2-3 to 2-5, wherein the extract of the Labiatae Menta plant is obtained by extraction with a polar solvent.
Item 2-7. (i) any one of Items 2-3 to 2-6, wherein the extract of the Labiatae Menta plant is obtained by extracting from a leaf, stem, or a mixed part thereof of the Labiatae Menta plant Food described in. Item 2-8. (ii) An extract of walnut family jaundice is obtained by extraction with a polar solvent,
The food according to any one of Items 2-3 to 2-7.
Item 2-9. (ii) The extract of walnut family jaundice is obtained by extracting from a walnut family jaundice leaf, stem, or a mixed site thereof, or any one of items 2-3 to 2-8 Food.
Item 2-10. The food according to any one of Items 2-3 to 2-9, further comprising (iii) theanine.
Item 2-11. The food according to any one of Items 2-3 to 2-10, further comprising (iv) at least one selected from the group consisting of ceramide and sugar ceramide.
Item 2-12. The food according to any one of Items 2-3 to 2-11, further comprising (iii) theanine, and (iv) at least one selected from the group consisting of ceramide and sugar ceramide.
Item 2-13. The food according to any one of Items 2-3 to 2-9, further comprising theanine, ceramide, and sugar ceramide.
Item 2-14. Item 14. The food according to any one of Items 2-3 to 2-13, which is a food indicated to be used for prevention or treatment of atopic dermatitis.

Furthermore, the present invention provides a pharmaceutical composition of the following aspect:
Item 3-1. Item 11. A pharmaceutical composition comprising the preventive or therapeutic agent for atopic dermatitis according to any one of Items 1-1 to 1-10.
Item 3-2. Item 11. A pharmaceutical composition for preventing or treating atopic dermatitis, comprising the agent for preventing or treating atopic dermatitis according to any one of Items 1-1 to 1-10.
Item 3-3. A pharmaceutical composition comprising (i) a Labiatae plant and / or an extract thereof, and (ii) a walnut jaundice and / or an extract thereof.
Item 3-4. Labiatae Mentha plant of the genus Mizuhakka (Mentha aquatica L.), peppermint (Mentha piperita L.), propenyl Royal mint (Mentha pulegium L.), Marubahakka (Mentha rotundifolia (L.) Huds. ), Spearmint (Mentha spicata The pharmaceutical composition according to Item 3-3, which is at least one selected from the group consisting of L.) and Bergamot mint ( Mentha citrata (Ehrh.) Briq.).
Item 3-5. Item 4. The pharmaceutical composition according to Item 3-3, wherein the Labiatae Menta plant is Atlantic mint.
Item 3-6. (i) The pharmaceutical composition according to any one of Items 3-3 to 3-5, wherein the extract of the Labiatae Menta plant is obtained by extraction with a polar solvent.
Item 3-7. (i) Any one of Items 3-3 to 3-6, wherein the extract of the Labiatae Menta plant is obtained by extracting from a leaf, stem, or a mixed site thereof of the Labiatae Menta plant A pharmaceutical composition according to 1.
Item 3-8. (ii) An extract of walnut family jaundice is obtained by extraction with a polar solvent,
Item 8. The pharmaceutical composition according to any one of Items 3-3 to 3-7.
Item 3-9. (ii) The extract of the walnut family jaundice is obtained by extracting from a walnut family jaundice leaf, stem, or a mixed part thereof, Pharmaceutical composition.
Item 3-10. The pharmaceutical composition according to any one of Items 3-3 to 3-9, further comprising (iii) theanine.
Item 3-11. The pharmaceutical composition according to any one of Items 3-3 to 3-10, further comprising (iv) at least one selected from the group consisting of ceramide and sugar ceramide.
Item 3-12. Item 13. The pharmaceutical composition according to any one of Items 3-3 to 3-11, further comprising (iii) theanine, and (iv) at least one selected from the group consisting of ceramide and sugar ceramide.
Item 3-13. Item 10. The pharmaceutical composition according to any one of Items 3-3 to 3-9, further comprising theanine, ceramide, and sugar ceramide.
Item 3-14. Item 14. The pharmaceutical composition according to any one of Items 3-3 to 3-13, which is a pharmaceutical composition for preventing or treating atopic dermatitis.
Item 3-15. Item 15. The pharmaceutical composition according to any one of Items 3-1 to 3-14, which is used in an internal form.
Item 3-16. Item 15. The pharmaceutical composition according to any one of Items 3-1 to 3-14, which is used in a form for external use.

Furthermore, this invention provides the cosmetics of the following aspect:
Item 4-1. Item 11. A cosmetic comprising the agent for preventing or treating atopic dermatitis according to any one of Items 1-1 to 1-10.
Item 4-2. Item 11. A cosmetic for preventing or treating atopic dermatitis, comprising the agent for preventing or treating atopic dermatitis according to any one of Items 1-1 to 1-10.
Item 4-3. A cosmetic comprising (i) a Labiatae plant and / or an extract thereof, and (ii) a walnut jaundice and / or an extract thereof.
Item 4-4. Labiatae Mentha plant of the genus Mizuhakka (Mentha aquatica L.), peppermint (Mentha piperita L.), propenyl Royal mint (Mentha pulegium L.), Marubahakka (Mentha rotundifolia (L.) Huds. ), Spearmint (Mentha spicata The cosmetic according to Item 4-3, which is at least one selected from the group consisting of L.) and Bergamot mint ( Mentha citrata (Ehrh.) Briq.).
Item 4-5. Item 4. The cosmetic according to Item 4-3, wherein the Labiatae Menta plant is Atlantic mint.
Item 4-6. (i) The cosmetic according to any one of Items 4-3 to 4-5, wherein the extract of the Labiatae Menta plant is obtained by extraction with a polar solvent.
Item 4-7. (i) Any one of Items 4-3 to 4-6, wherein the extract of the Labiatae Menta plant is obtained by extracting from a leaf, stem, or a mixed site thereof of the Labiatae Menta plant Cosmetics described in 1.
Item 4-8. (ii) An extract of walnut family jaundice is obtained by extraction with a polar solvent,
Item 4. The cosmetic according to any one of Items 4-3 to 4-7.
Item 4-9. (ii) The extract of walnut family jaundice is obtained by extracting from a walnut family jaundice leaf, stem, or a mixed portion thereof, or any one of items 4-3 to 4-8 Cosmetics.
Item 4-10. The cosmetic according to any one of Items 4-3 to 4-9, further comprising (iii) theanine.
Item 4-11. The cosmetic according to any one of Items 4-3 to 4-10, further comprising (iv) at least one selected from the group consisting of ceramide and sugar ceramide.
Item 4-12. The cosmetic according to any one of Items 4-3 to 4-11, further comprising (iii) theanine, and (iv) at least one selected from the group consisting of ceramide and sugar ceramide.
Item 4-13. Item 14. The cosmetic according to any one of Items 4-3 to 4-12, which is a cosmetic for preventing or treating atopic dermatitis.

Hereinafter, the present invention will be described in detail.
1. The preventive or therapeutic agent for atopic dermatitis of the present invention The preventive or therapeutic agent for atopic dermatitis of the present invention comprises (i) Labiatae plant and / or extract thereof, and (ii) Walnut jaundice and / Or the extract is contained as an active ingredient, It is characterized by the above-mentioned. Hereinafter, a preventive or therapeutic agent for atopic dermatitis is referred to as “preventive or therapeutic agent”; (i) a Labiatae plant and / or an extract thereof as “(i) component”; (ii) walnut jaundice And / or its extract may be referred to as “component (ii)”.

(i) Menaceae (Mentha) genus plant used as a component has been conventionally used as a food raw material, and is known as a plant whose safety has been confirmed. The Labiatae Mentha genus plants which may be used in the present invention is not particularly limited, for example Mizuhakka (Menthaaquatica L.), peppermint (Mentha piperita L.), propenyl Royal mint (Menthapulegium L.), Marubahakka (Mentha rotundifolia (L.) Huds.), Dutch mint ( Menthaspicata L.), Bergamot mint ( Mentha citrata (Ehrh.) Briq.), And the like. Preferred is mint. In addition, the Labiatae Menta genus plant used for this invention may be a wild species, and the thing by which breed | variety improvement was carried out.

In addition, the Labiatae Menta plant used as the component (i) may be the whole plant of the plant or any part of the plant such as flowers, buds, leaves, stems, roots, rhizomes, and seeds. Preferably, mention may be made of leaves and stems. These sites can be used alone or in combination of two or more.

(i) When a Labiatae plant is used as a component, the plant may be subjected to treatments such as drying, shredding, crushing, and grinding.

In addition, the extract of Lamiaceae Menta genus plant used as component (i) is the aforementioned Lamiaceae Menta genus plant as an extraction raw material, which is dried, shredded, crushed, pulverized as it is or as necessary. It can be obtained by subjecting it to extraction, boiling, or fermentation treatment with a solvent. In addition, about an extraction raw material, you may degrease in advance with nonpolar solvents, such as hexane, as a pretreatment as needed. By performing such degreasing treatment, excess lipid in the extraction raw material can be removed, and in some cases, it can contribute to deodorization of the extraction raw material.

  Examples of the solvent used for the extraction treatment of the extract of the genus Menaceae include polar solvents such as water, polar organic solvents, and mixed liquids of water and polar organic solvents. Examples of the polar organic solvent include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, butanol, and isopropanol; propylene glycol; acetone; ethyl acetate alone, or combinations of two or more thereof. Among the polar solvents, from the viewpoint of safety to the human body and handleability, preferably water; lower alcohols having 2 to 4 carbon atoms such as ethanol, propanol, butanol; or a mixture thereof. More preferred is water, ethanol, or a mixture thereof, and particularly preferred is water. When a mixed liquid of a lower alcohol having 1 to 5 carbon atoms and water is used as the extraction solvent, the content ratio of the lower alcohol to the total weight of the mixed liquid is, for example, 0.1 to 99.9% by weight, preferably Is 0.1 to 70% by weight, more preferably 0.1 to 50% by weight.

  The extraction process is performed, for example, using about 5 to 20 parts by weight of an extraction solvent with respect to 1 part by weight of an extraction raw material of a Labiatae plant. Further, as the extraction treatment method, a conventionally used extraction method for plant extracts can be adopted, and specifically, immersion methods such as immersion and digestion; low temperature, room temperature or high temperature. Examples include a stirring method; or a percolation method. As a specific example of the extraction process of the extract of the genus Menaceae, the dried raw material of the genus Menta is pulverized, and about 5 to 20 parts by weight of an extraction solvent is added to 1 part by weight of the dried pulverized product. An example is a method in which, after 1 hour to 5 hours of addition with stirring at room temperature, the solid content is removed by a conventional solid-liquid separation means such as filtration or centrifugation to obtain a solution fraction. .

  The extract of Labiatae belonging to the genus Menaceae obtained by the above method is in a liquid state, and in the present invention, the extract can be used as it is, but when an organic solvent is contained, it is obtained by distillation under reduced pressure or the like. It is preferred to remove the organic solvent. Further, if necessary, it can be used as a dried product by removing moisture by subjecting it to a drying treatment such as reduced pressure drying, freeze drying, spray drying or the like. In addition, as an extract of the Labiatae Menta plant, a commercially available product can be used.

In the preventive or therapeutic agent of the present invention, as the component (i), either one of the Labiatae plant or the extract thereof may be used, or both of the Labiatae plant and the extract thereof are combined. May be used. The component (i) is preferably an extract of a Labiatae Menta plant.

On the other hand, in the preventive or therapeutic agent of the present invention, (ii) walnut family japonicum ( Engelhardtia chrysolepis ) used as a component is an evergreen tree of the walnut family that grows naturally in the mountains of southern China, It is a highly safe plant that is drunk as tea. The walnut family jaundice used in the present invention may be a wild species or an improved variety.

  In addition, as the walnut family jaundice used as the component (ii), any of the whole tree of the plant or a part of the plant such as a stem, a leaf, a root, a rhizome, but preferably a leaf and a stem, More preferably, a leaf can be mentioned. These sites can be used alone or in combination of two or more.

  (ii) When walnuts are used as a component, the plant may have been subjected to treatments such as drying, shredding, crushing, and grinding.

  In addition, the extract of walnut family jaundice used as the component (ii) is the above walnut family jaundice as an extraction raw material, which is dried, shredded, crushed, pulverized, or pressed as it is or as necessary. It can be obtained by subjecting it to boiling or fermentation treatment and extraction with a solvent. In addition, about the extraction raw material, you may degrease in advance with nonpolar solvents, such as hexane, as a pretreatment as needed like the case of Labiatae plant.

  The extraction solvent and the extraction treatment method used for the extraction treatment of the walnut family jaundice extract are the same as in the case of the extract of the Labiatae plant.

  The extract of the walnut family jaundice may be in the form of a liquid as in the case of the above-mentioned extract of the genus Menaceae, or may be in the form of a concentrate or a dried product.

  The extract of walnuts jaundice contains diflavonol glycosides such as neoastilbine, astilbine, neoisoastilbine, isoastilbine, funxoxide E, quercitrin, and eucriffin as main components.

In the preventive or therapeutic agent of the present invention, as the component (ii), only one of walnut jaundice or an extract thereof may be used, or both walnut jaundice and an extract thereof are used in combination. May be. The component (ii) is preferably an extract of walnut family jaundice.

In the preventive or therapeutic agent of the present invention, the mixing ratio of the component (i) and the component (ii) is, for example,
In terms of dry weight, with respect to 1 part by weight of component (i), component (ii) is 0.001 to 1000 parts by weight,
Preferably it is 0.01-100 weight part, More preferably, 0.1-10 weight part is illustrated. In such a combination ratio, by containing a combination of component (i) and component (ii) (especially extracts of Lamiaceae Menta plants and walnuts jaundice), atopic dermatitis The preventive or therapeutic effect is enhanced synergistically.

  The preventive or therapeutic agent of the present invention may contain (iii) theanine in addition to the components (i) and (ii). By containing theanine, a sedative action and a relaxing action can be imparted, and a mental improvement effect that is said to be a cause of atopic dermatitis is obtained.

When the preventive or therapeutic agent of the present invention contains theanine, the blending ratio of theanine in the agent is not particularly limited, but the total amount (in terms of dry weight) of the above components (i) and (ii) is 100.
The proportion of theanine is usually 0.001 to 100 parts by weight, preferably 0.01 to 100 parts by weight, and more preferably 0.1 to 50 parts by weight with respect to parts by weight.

Further, the preventive or therapeutic agent of the present invention may contain at least one selected from the group consisting of (iv) ceramide and sugar ceramide in addition to the components (i) and (ii) above. . By containing ceramide and / or sugar ceramide, there is a tendency that the effect of improving skin symptoms is improved. Examples of the ceramide used in the present invention include those derived from mammals such as cattle and horses; those derived from plants such as rice bran and rice germ; and those produced by chemical synthesis. Examples of the sugar ceramide used in the present invention include glucosyl ceramide, galactosyl ceramide and the like, derived from mammals such as cow and horse; derived from plants such as rice bran and rice germ; Examples thereof include those produced by chemical synthesis. In the present invention, the ceramide / and / or sugar ceramide does not necessarily have to be purified. For example, rice germ oil containing ceramide / and / or sugar ceramide can also be used.

Further, when the preventive or therapeutic agent of the present invention contains ceramide and / or sugar ceramide, the mixing ratio of ceramide and / or sugar ceramide is not particularly limited, but the above (i) and (ii)
The total amount of ceramide and / or sugar ceramide is usually 0.001 to 100 parts by weight, preferably 0.005 to 10 parts by weight, more preferably 0.01 to 100 parts by weight of the total amount of components (in terms of dry weight). The ratio which becomes -5 weight part is mentioned.

As a preferred embodiment of the preventive or therapeutic agent of the present invention, there may be mentioned those containing (iii) theanine and (iv) ceramide / and / or sugar ceramide in addition to the components (i) and (ii). By including these components (iii) and (iv) in combination, there is a tendency that the prevention or treatment effect of atopic dermatitis tends to be better, and the sensibility of the treatment effect is increased. can get.

  The preventive or therapeutic agent of the present invention can exert a preventive or therapeutic effect on atopic dermatitis, whether used by oral ingestion or administration, or used by transdermal application. It can be used in fields such as cosmetics.

  The effective application amount of the preventive or therapeutic agent of the present invention is appropriately set according to the form of the agent, the age and sex of the subject, the expected effect, the type of active ingredient to be used, and the like.

  For example, when the preventive or therapeutic agent of the present invention is orally ingested or administered, the total amount of the above components (i) and (ii) is usually used as an effective amount (in terms of dry weight) of the agent per day for an adult. Is an amount corresponding to 0.006 to 6 g, preferably 0.14 to 5 g. More specifically, as an effective daily amount (in terms of dry weight) for an adult when ingested or administered, (i) component is 0.05 to 5 g, and (ii) component is 0.01 to 2 g. Preferably an amount corresponding to 0.1 to 3 g of component (i) and 0.04 to 1 g of component (ii).

In addition, for example, when the preventive or therapeutic agent for atopic dermatitis of the present invention is applied transdermally (externally), the dry weight is usually used as an effective amount of the agent per day for 1 cm ² of the affected part of an adult. In terms of conversion, the total amount of the above components (i) and (ii) is exemplified by an amount corresponding to 0.001 to 0.1 g, preferably 0.003 to 0.05 g. More specifically, as an effective amount per day for 1 cm ² of the affected part of an adult, (i) component is 0.0008 to 0.08 g, and (ii) component is 0.0002 to 0.02 g; preferably The amount of component (i) is 0.002 to 0.06 g and the amount of component (ii) is 0.0007 to 0.015 g.

2. Food The food which exhibits the preventive or therapeutic effect of atopic dermatitis is provided by adding the preventive or therapeutic agent of the present invention to food. That is, the food containing the preventive or therapeutic agent of the present invention is labeled as a food for the prevention or treatment of atopic dermatitis, in particular, used for the prevention or treatment of atopic dermatitis. Useful as food.

  The food containing the preventive or therapeutic agent of the present invention is preferably a health functional food (nutrient functional food and food for specified health use), so-called health food, nutritional supplement food or special use food (food for patients etc.), etc. Can be mentioned. Examples of forms include beverages (carbonated beverages, soft drinks, milk beverages, coffee beverages, mineral water, alcoholic beverages, fruit juice beverages, teas, nutritional beverages, etc.), powdered beverages (powdered juice, powdered soups, etc.), confectionery (Gum, candy, cookies, rice crackers, biscuits, jelly, etc.), fishery products (rice cakes, bamboo rings, etc.), livestock products (ham, sausages, etc.), seasonings (sauce, mayonnaise, sprinkles, spices, dressings, etc.), bread, Examples include noodles and cereals. Moreover, in the case of health functional foods, dietary supplements, etc., those in the form of tablets, granules, capsules, powders, syrups, jellies and the like can be mentioned.

In the food containing the preventive or therapeutic agent of the present invention, the blending ratio of the agent in the food is appropriately set according to the effective amount and the form of the food. As an example, the total amount of the components (i) and (ii) is 1 to 100% by weight in terms of dry weight, preferably 10 to 90% by weight, and more preferably 15 to 80% by weight with respect to the total amount of the food. Examples of the ratio are%. More specifically, in terms of dry weight, the component (i) is 10 to 80% by weight and the component (ii) is 3 to 50% by weight, preferably (i) based on the total weight of the food. The component is 13 to 70% by weight, and the component (ii) is 5 to 30% by weight; more preferably, the component (i) is 15 to 60% by weight, and the component (ii) is 15 to 25% by weight. The ratio is illustrated.

In addition, when theanine is blended in a food together with the components (i) and (ii), the theanine content in the food is the theanine content in the preventive or therapeutic agent or the effective amount of the agent. It sets suitably according to etc. As an example, the proportion of theanine is 1 to 80% by weight, preferably 2 to 60% by weight, and more preferably 4 to 30% by weight with respect to the total amount of the food.

  Further, when ceramide / and / or sugar ceramide is blended with food together with the above components (i) and (ii), the blending ratio of ceramide / and / or sugar ceramide in the food is as follows. It is appropriately set according to the blending ratio of the above and the above-mentioned effective amount of the agent. As an example, the ratio of ceramide / and / or sugar ceramide in the total amount of 0.01 to 80% by weight, preferably 0.1 to 5% by weight, more preferably 0.3 to 3% by weight with respect to the total amount of food. Can be mentioned.

3. Cosmetics The cosmetics exhibiting the effect of preventing or treating atopic dermatitis are provided by preparing cosmetics by mixing the preventive or therapeutic agent of the present invention together with a cosmetically acceptable base or carrier. The That is, the cosmetic containing the preventive or therapeutic agent for atopic dermatitis of the present invention is useful as a cosmetic for preventing or treating atopic dermatitis.

  The form of the cosmetic is not particularly limited, and examples thereof include cleansing agents, skin cleansing agents, massage agents, ointments, creams, lotions, oils, packs, face wash, lotion, milky lotion, jelly and the like.

In the cosmetic containing the preventive or therapeutic agent of the present invention, the blending ratio of the agent in the cosmetic is appropriately set according to the effective amount, the form of the cosmetic, and the like. As an example, the total amount of the components (i) and (ii) is 0.1 to 15% by weight in terms of dry weight, preferably 0.5 to 7% by weight, and more preferably based on the total amount of the cosmetic. A ratio of 1 to 5% by weight is exemplified. More specifically, with respect to the total amount of the cosmetic, the component (i) is 0.01 in terms of dry weight.
10 to 10% by weight and (ii) component 0.1 to 10% by weight; preferably (i) component 0.05 to 5% by weight and (ii) component 0.2 to 5% by weight %; More preferably, the proportion of the component (i) is 0.1 to 3% by weight and the component (ii) is 0.3 to 3% by weight.

Further, when theanine is blended in cosmetics together with the above components (i) and (ii), the theanine blending ratio in the food, the blending ratio of theanine in the preventive or therapeutic agent and the effective of the agent It is set as appropriate according to the amount and the like. As an example, the proportion of theanine is 0.01 to 10% by weight, preferably 0.05 to 5% by weight, more preferably 0.1 to 3% by weight, based on the total amount of the cosmetic. .

Further, when ceramide / and / or sugar ceramide is blended with cosmetics together with the above components (i) and (ii), the blending ratio of ceramide / and / or sugar ceramide in the cosmetic is as described in the above preventive or therapeutic agent. The ceramide is appropriately set according to the blending ratio of the ceramide and the effective amount of the agent. As an example, the total amount of ceramide / and / or sugar ceramide is 0.001 to 5% by weight, preferably 0.005 to 3% by weight, more preferably 0.01 to 1% by weight, based on the total amount of cosmetics. A percentage can be mentioned.

4). Pharmaceutical composition The preventive or therapeutic agent of the present invention is provided as a pharmaceutical composition for the prevention or treatment of atopic dermatitis by being formulated with a pharmaceutically acceptable base or carrier as necessary. The The pharmaceutical composition may be used in an internal form or may be used in an external form.

  Examples of the pharmaceutical composition used in the internal form include oral preparations such as tablets, powders, granules, capsules, pills, troches, liquids and extracts; and dosage forms such as injections. It is done.

  Examples of the pharmaceutical composition used in an external form include those in dosage forms such as ointments, patches, solutions, emulsions, and nasal propellants.

  In addition, about the compounding ratio of this agent in the pharmaceutical composition containing the preventive or therapeutic agent of this invention, it can set suitably according to the form of this pharmaceutical composition, the said administration effective dose, etc. For example, if it is a pharmaceutical composition used in an internal form, the ratio of each compounding component in this pharmaceutical composition is set to the same ratio as the said foodstuff. Moreover, if it is a pharmaceutical composition used with an external form, the ratio of each compounding component in this pharmaceutical composition will be set to the same ratio as the case of said cosmetics.

5. Atopic dermatitis predisposition to improve atopic dermatitis preventive or therapeutic agent of atopic dermatitis according to the present invention has the effect of improving atopic dermatitis predisposition to make it difficult to develop atopic dermatitis Can do. Therefore, the preventive or therapeutic agent for atopic dermatitis of the present invention is also useful as an agent for improving the predisposition to atopic dermatitis. The “atopic dermatitis predisposing constitution” in the present invention means a constitution that easily produces IgE antibody and easily develops atopic dermatitis by contact with an allergen.

  The preventive or therapeutic agent of the present invention contains a combination of an extract of Lamiaceae Menta plant and an extract of Walnut jaundice, thereby synergistically enhancing the preventive or therapeutic effect against atopic dermatitis. Therefore, it is remarkably superior in the prevention or treatment effect of atopic dermatitis as compared with the case of using the extract of Lamiaceae Menta genus plant and the extract of Walnut jaundice alone.

  In addition, the extract of Labiatae Menta plant and the extract of Walnut jaundice used in the preventive or therapeutic agent for atopic dermatitis of the present invention are conventionally used as food ingredients and have been confirmed to be safe. Yes. Therefore, the preventive or therapeutic agent for atopic dermatitis of the present invention can be incorporated into foods and cosmetics, and prevention of atopic dermatitis through daily and simple means of food intake and use of cosmetics. Or treatment can be realized.

  The preventive or therapeutic agent for atopic dermatitis according to the present invention has an action to improve skin symptoms such as rough skin, acne, bruise, chapped skin, dry skin, eczema, moisturized skin as well as preventive or therapeutic action against atopic dermatitis. As shown, it is highly useful.

EXAMPLES Hereinafter, although an Example etc. are given and this invention is demonstrated, this invention is not limited to these Examples.
Reference Production Example 1 Production of mint mint extract 10 L of water was added to 1000 g of dried mint leaves, and reflux extraction was performed for 1 hour. Next, the obtained extract was concentrated under reduced pressure to about 2 L, 360 g of dextrin was added thereto, this was spray-dried, and powder containing 720 g of mint extract (substantially 360 g of extract of mint) Content) was obtained (yield 36%).

Reference Production Example 2 Manufacture of walnut family japonica extract 200 g of dried pulverized corn leaves were extracted with 2 liters of hot water for 2 hours, and the resulting extract was concentrated under reduced pressure to give 32 g of extract (dried product). ) It was confirmed that the obtained extract contained 2.28% by weight of neoastilbine, 3.87% by weight of astilbine, 2.71% by weight of neoisoastilbine, and 0.81% by weight of isoastilbine. It was done.

Test example 1
Tablets with the composition shown in Table 1 were prepared according to a conventional method, and were taken by 8 monitors (2 males, 6 females) suffering from atopic dermatitis for 3 consecutive days for 3 consecutive days. I let you. Within 7 days from the end of intake, the degree of improvement in symptoms of atopic dermatitis was determined for each monitor according to the following evaluation criteria.
<Degree of improvement in symptoms of atopic dermatitis>
◎: The symptoms of atopic dermatitis are clearly improved, and the therapeutic effect is clearly recognized. ○: The symptoms of atopic dermatitis are improved to the extent that it can be recognized, and the therapeutic effect is observed. △: Atopic Deterioration of dermatitis symptoms was suppressed ×: Atopic dermatitis symptoms worsened

  The obtained results are shown in Table 2. From these results, it was confirmed that taking a tablet containing mint extract and walnut family jaundice extract has the effect of improving the symptoms of atopic dermatitis, preventing or treating atopic dermatitis It has become clear that it is effective to use a mint extract and a walnut family jaundice extract in combination.

Test example 2
Using mint extract powder as an extract of mint and jaundice leaf extract as an extract of walnut family, the suppression rate of ear swelling was measured in mice in which atopic dermatitis was induced.

  As the mouse, a male NC / NgaTndCrjSPF mouse (hereinafter referred to as NC mouse: purchased from Nippon SLC Co., Ltd.) was used. The animals were purchased at 5 weeks of age, and after an acclimatization period of 1 week, they were subjected to the experiment from 6 weeks of age.

  As test substances, mint extract powder (trade name: peppermint extract powder T-0602 manufactured by Ginger Nutrition Co., Ltd .; hereinafter referred to as peppermint extract), twilight leaf extract powder (trade name: twilight leaf extract powder T-0527 raw The following were manufactured by Sakai Nutrition Pharmaceutical Co., Ltd .; Peppermint extract is prepared by drying hot water extract from mint leaves and adding dextrin to a final concentration of dextrin of 50%. The yellow coconut leaf extract is obtained by drying a hydrous alcoholic extract from yellow cocoon leaves and adding dextrin to the final concentration of dextrin to 20%.

  As a control substance, epinastine hydrochloride (trade name: Alesion (registered trademark) dry syrup 1% Nippon Boehringer Ingelheim Co., Ltd.) was used. Saline (Otsuka Pharmaceutical Co., Ltd.) was used for preparation of the administration specimen.

  The group composition and dose are as follows: a group not subjected to sensitization and induction (group a: no treatment group), a group subjected to sensitization and induction and administered with physiological saline (group b: negative control group), sensitization and induction Group administered with epinastine hydrochloride 5 mg / kg / day (group c: positive control group), sensitized and induced, group administered with peppermint extract 100 mg / kg / day (group d), sensitized and induced yellow jade leaves Group (e group) administered with 100 mg / kg / day of extract, sensitized and induced group (group f) administered with 30 mg / kg / day of yellow coconut leaf extract, peppermint extract 100 mg / kg / day + citrus extract with sensitized and induced Seven groups were administered (group g) to which 30 mg / kg / day was administered.

  For grouping, the body weight was measured on the day before the sensitization treatment, and the group was divided into 6 animals per group so that the variation in body weight was almost uniform. In addition, administration was orally administered at a rate of 0.01 ml / g using a stomach tube. The administration period was once a day from the day before the sensitization treatment day to the end of the 9th week.

  Sensitization was performed once on animals that reached 6 weeks of age. That is, shaving the animal abdomen using clippers, and the next day, 100 μL of 5% (w / v) picric chloride (Tokyo Chemical Industry Co., Ltd.) solution (ethanol: acetone = 4: 1) was applied to the mouse abdomen. It was applied using Pipetman (GILSON).

  The picryl chloride used for sensitization / induction in this test example is one of the so-called haptens. A hapten is generally a low molecular weight substance having a molecular weight of 5000 or less and binds to an antibody but does not have immunogenicity by itself. However, haptens acquire immunogenicity by binding to other substances such as proteins and polysaccharides, and act as allergens in this test example.

  Induction of atopic dermatitis started 4 days after sensitization. The first 6 weeks were conducted once a week on Monday. After that, it was conducted twice a week on Mondays and Thursdays in the 7th and 8th weeks. For induction, 20 μL of 1% (w / v) picric chloride solution (olive oil: acetone = 9: 1) was applied to the back of the left and right auricles of the mouse under anesthesia with ether.

  For the b, c and g groups at the end of the 9th week of induction, the thickness of the left and right auricles was measured using a micrometer (Mitutoyo Corporation), and the obtained measured values were averaged. Based on the obtained average value, the positive control (group c) was 100%, the negative control (group b) was 0%, and the ear swelling suppression rate of group g was determined. The results are shown in Table 3.

  In the above test, the inflammation findings of each mouse were recorded. As for dermatitis findings, the condition of the skin behind the left and right auricles was observed once a week on the next day (Tuesday). The evaluation criteria are based on the evaluation criteria for clinical symptoms of human atopic dermatitis. (1) Redness / bleeding, (2) Abrasion / tissue defect, (3) Crust formation / drying, graded in 4 stages (0: asymptomatic, 1: mild, 2: moderate, 3: advanced), the scores (inflammation scores) were averaged for the left and right auricles, and the standard deviation was determined. In addition, a significant difference with respect to the negative control group (group b) at the end of the 9th week of induction was determined by t test. The results are shown in Table 3.

  As shown in Table 3, the g group using the peppermint extract and the yellow leaf extract together has a lower inflammation score than the b group (negative control group) or the group used alone (groups df). It was done. Moreover, the g group showed the pinna swelling suppression rate comparable as the positive control group c group.

  For the a, b, c, and g groups, photographs showing the swelling of the mouse auricle were taken (FIG. 1).

  From the above results, the combined use of mint mint extract and walnut family jaundice extract significantly enhances the effect of improving the symptoms of atopic dermatitis compared to the case where they are used alone. It was confirmed that

Formulation Example 1 Tablets Tablets having the following composition were produced according to a conventional method.

Formulation amount per tablet (mg)
Atlantic mint extract obtained in Reference Production Example 1 51.0
Walnut extract obtained in Reference Production Example 2 22.1
Theanine 16.0
Rice germ oil containing ceramide glycolipid
(Contains 37.5% by weight of ceramide glycolipid) 1.6
Powdered reduced maltose 100.0
Starch 0.28
Calcium carbonate 2.1
Dextrin 56.5
Crystalline cellulose 34.42
Sucrose fatty acid ester 15.0
Total amount per tablet (mg) 300.0

Formulation Example 2 Cream (Cosmetic)
A cosmetic cream having the following composition was produced according to a conventional method.

Mixing ratio (wt%)
Atlantic mint extract obtained in Reference Production Example 1 1
Walnut department jaundice extract obtained in Reference Production Example 2 1
Ethanol 6
Beeswax 7
Squalane 28
Fatty acid glyceryl ester 4
Emulsifier 5
1,3-butylene glycol 3
α-bisabolol 0.3
Purified water
100% by weight

Formulation Example 3 Ointment An ointment having the following composition was produced according to a conventional method.

Mixing ratio (wt%)
Mint extract 1.5 obtained in Reference Production Example 1.5
Walnut jaundice extract obtained in Reference Production Example 2 1.5
White petrolatum 25
Stearyl alcohol 22
Propylene glycol 12
Sodium lauryl sulfate 15
Methyl paraoxybenzoate 0.02
Propyl paraoxybenzoate 0.015
Purified water
100% by weight

It is a photograph which shows the typical example of the pinna of the mouse | mouth of a group of a, b, c, and g at the time of completion | finish of the 9th week of atopic dermatitis induction.

Claims (4)

(i) Mental (Mentha) genus plant and / or an extract thereof, and (ii) Engelhardtia chrysolepis and / or an extract thereof as an active ingredient for preventing or preventing atopic dermatitis Therapeutic agent. A food containing (i) a Labiatae plant and / or an extract thereof, and (ii) a walnut jaundice and / or an extract thereof. A pharmaceutical composition comprising (i) a Labiatae plant and / or an extract thereof, and (ii) a walnut jaundice and / or an extract thereof. A cosmetic comprising (i) a Labiatae plant and / or an extract thereof, and (ii) a walnut jaundice and / or an extract thereof.